Mizuho Markets Cayman LP Has $67.37 Million Stock Holdings in Eli Lilly and Company $LLY

Mizuho Markets Cayman LP boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 2,166.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 88,300 shares of the company’s stock after buying an additional 84,404 shares during the quarter. Eli Lilly and Company makes up 2.3% of Mizuho Markets Cayman LP’s holdings, making the stock its 7th biggest holding. Mizuho Markets Cayman LP’s holdings in Eli Lilly and Company were worth $67,373,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marshall Investment Management LLC acquired a new position in Eli Lilly and Company during the third quarter worth about $2,576,000. Moors & Cabot Inc. boosted its stake in shares of Eli Lilly and Company by 1.3% in the 3rd quarter. Moors & Cabot Inc. now owns 22,295 shares of the company’s stock valued at $17,011,000 after purchasing an additional 284 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in shares of Eli Lilly and Company by 10.0% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 126,500 shares of the company’s stock valued at $95,051,000 after purchasing an additional 11,461 shares during the last quarter. Mindset Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 5.5% during the 3rd quarter. Mindset Wealth Management LLC now owns 1,245 shares of the company’s stock valued at $950,000 after purchasing an additional 65 shares during the last quarter. Finally, Mirabella Financial Services LLP increased its position in Eli Lilly and Company by 112.2% during the 3rd quarter. Mirabella Financial Services LLP now owns 5,365 shares of the company’s stock worth $4,085,000 after purchasing an additional 2,837 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Wall Street bullishness: Several firms (including Bernstein/SocGen and mentions at Goldman) reiterated Outperform or high price targets (one cited $1,300), citing Lilly’s GLP‑1 leadership and the new Employer Connect program to broaden access to obesity meds. Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans
• Positive Sentiment: Clinical/regulatory upside — EBGLYSS (lebrikizumab) Phase 3 pediatric topline: strong skin‑clearance and itch relief in children (6 months–18 years), supporting potential label expansion and strengthening Lilly’s immunology/dermatology growth story. Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes…
• Positive Sentiment: Capacity and market expansion: Reuters/Yahoo report that Lilly plans ~$3 billion investment in China over the next decade to build production capacity for orforglipron (oral GLP‑1), which could ease supply constraints if approved and support global rollout. Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports
• Neutral Sentiment: Share structure chatter: Commentary that LLY could be a candidate for a future stock split (given high absolute price and growth) keeps the name on retail radars but is not an immediate fundamental change. 3 Stocks That Could Be Next to Announce a Stock Split (LLY)
• Neutral Sentiment: Congressional buying: Disclosed purchases by a member of Congress add anecdotal interest but are delayed disclosures and not a direct catalyst. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: Emerging competitive risk — Structure Therapeutics and others reported strong midstage oral GLP‑1 weight‑loss results that at times rival injectables; market reaction to those data and speculation about takeover candidates increase competitive uncertainty for Lilly’s obesity franchise. Structure Weight-Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Valuation concerns: Commentary (The Motley Fool and others) warns that a high multiple and heavy bullish expectations leave LLY exposed to downside if growth or margin assumptions slip. Is There Too Much Bullishness Priced Into Eli Lilly’s Stock Price?

Eli Lilly and Company Trading Up 0.3%

Shares of NYSE LLY opened at $987.83 on Tuesday. The firm has a 50 day moving average price of $1,036.20 and a two-hundred day moving average price of $954.12. The stock has a market cap of $933.32 billion, a P/E ratio of 43.04, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on LLY shares. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Morgan Stanley reiterated an “overweight” rating and set a $1,313.00 price target on shares of Eli Lilly and Company in a report on Thursday, March 5th. HSBC reiterated a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Royal Bank Of Canada assumed coverage on Eli Lilly and Company in a research report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price objective on the stock. Finally, Argus upped their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,229.59.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.